IKAR

Pharmaceutical ManufacturingRussia501-1000 Employees

Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies (drugs and devices) designed to address the significant needs of critically ill patients. The company’s lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package is marketed in the USA, Puerto Rico, Canada, Australia, Mexico and Japan

Sign up for free to view info

Email Format Employee directory